Insight Molecular Diagnostics Inc. (IMDX)
Health Care · Molecular diagnostics / transplant rejection monitoring · NASDAQ
iMDx develops decentralized molecular diagnostic kits for transplant organ rejection monitoring using donor-derived cell-free DNA biomarkers, enabling in-house testing at hospitals rather than centralized lab services.
What Insight Molecular Diagnostics Inc. does
Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation) is a diagnostics technology company developing molecular diagnostic test kits for organ transplant rejection monitoring and oncology applications. The company's primary focus is decentralized transplant testing through its GraftAssure family of assays, which measure donor-derived cell-free DNA (dd-cfDNA) using digital PCR instruments manufactured by Bio-Rad. iMDx operates a CLIA-certified laboratory in Franklin, Tennessee for clinical testing (GraftAssureCore LDT), develops research-use-only kits (GraftAssureIQ), and is pursuing FDA approval for its clinical IVD kit (GraftAssureDx). The company pursues a business model enabling in-house testing at hospitals and transplant centers rather than centralized send-out laboratory services.
Themes: transplant rejection monitoring, decentralized clinical testing, organ health diagnostics, oncology precision medicine, digital PCR diagnostics
Fundamentals
- Price$4.30 as of 2026-08-26 close
- Market cap$141M as of 2026-08-26
- 1-year return+71.3% 2025-08-26 close $2.51 → 2026-08-26 close $4.30
- P/En/a negative earnings
- Net margin-2454.6% as of 2026-08-27
- Gross margin+51.3% as of 2026-08-27
- ROE-426.7% as of 2026-08-27
- Debt / equity0.92 as of 2026-08-27
- Revenue growth (YoY)-49.3% as of 2026-08-27
- Revenue CAGR (3y)+61.8% SEC XBRL
- Beta1.83 as of 2026-08-27
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How IMDX compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-27
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-27
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-27
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-27
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Insight Molecular Diagnostics Inc. looks technically
Insight Molecular Diagnostics Inc. (IMDX) is trading 19.8% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 80 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 10 trading days ago. It is 49.5% below its highest point of the past year. Trading volume is unusually light — only about 25% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 19.8% below its 200-day average, the long-term trend line — a long-term downtrend | -19.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.86 | $4.86 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.36 | $5.36 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 80 trading days ago — a "death cross", a bearish long-term signal | 80 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 29, with sellers in control | 28.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($3.55 to $4.93) — its "stochastic" reading is 54 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 54.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.51 | $8.51 |
|---|---|---|
| From the 52-week high | it is 49.5% below its 52-week high (its highest price of the past year) | -49.5% |
| Above the 52-week low | it is 84.5% above its 52-week low (its lowest price of the past year) | +84.5% |
| Below the 52-week high | it is 49.5% below its highest point of the past year | 49.5% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $204.80 (set on 2016-01-05) | $204.80 |
| Given back of the 52-week move | over the past year its closes ranged ($2.40 to $8.48), and it has given back well over two thirds of its rise from last year’s low — 69% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.53 to $4.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 68.8% |
| From the all-time high | it is 97.9% below its all-time high | -97.9% |
| Nearest price level | it is trading 0.9% above a support level at $4.26 — a price it turned at twice since 2025-06-20, most recently on 2026-07-14. Since 2024-08-26 it has 12 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.9% |
| All-time low | its lowest closing price on record is $1.92 (set on 2025-01-22) | $1.92 |
| Above the all-time low | it is 123.7% above its all-time low | +123.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.343 between its high and its low — about 8.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.343 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.87 and $5.17 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.87 – $4.52 – $5.17 |
| Typical daily range (% of price) | its price moves about 8.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.0% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges below its 200-day average price (19.8% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 25% of its 30-day average | 0.25× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-26 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.7% |
|---|---|---|
| Gap filled | a 2.3% gap up opened on 2026-08-21 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 2 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.0 percentage points (the stock lost 9.3% while the market gained 3.7%) | -13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 32.1 percentage points (the stock lost 29.4% while the market gained 2.7%) | -32.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 35.3 percentage points (the stock lost 24.2% while the market gained 11.1%) | -35.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 52.6 percentage points (the stock gained 71.3% while the market gained 18.7%) | +52.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.1% of the share price. | -13.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.67 — a volume-weighted average of daily closes over 153 sessions, not a true tick-by-tick VWAP. | -8.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.16 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +3.5% |
Price levels it has turned at before
IMDX last closed at $4.30 on 2026-08-26. Since 2024-08-26 it has turned at 12 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.26 | Support | 0.9% below the last close | turned there twice · 2025-06-20 to 2026-07-14 |
| $4.55 | Resistance | 5.8% above the last close | turned there twice · 2026-04-21 to 2026-06-18 |
| $4.75 | Resistance | 10.6% above the last close | turned there three times · 2025-03-11 to 2026-03-02 |
| $3.57 | Support | 16.9% below the last close | turned there twice · 2025-09-16 to 2026-08-13 |
| $3.48 | Support | 19.1% below the last close | turned there twice · 2025-04-25 to 2025-05-22 |
| $5.33 | Resistance | 23.9% above the last close | turned there twice · 2026-05-04 to 2026-08-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Most volatile (6%+ typical daily range) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.25 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$8.33 range $4.00 – $12.00; median $9.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMDX
- Consensus EPS estimate-$0.23 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Regulatory approval dependency: GraftAssureDx requires FDA marketing authorization for clinical use in the U.S. and IVDR approval in the EU, with no guarantee of timely or favorable decisions","Dependence on Bio-Rad partnership: the company's assays rely on Bio-Rad's digital PCR instruments, and disruption of this collaboration could materially impact product development and commercialization","Steep revenue decline and negative profitability: revenue decreased 49.28% year-over-year with a net margin of -2454.64%, indicating substantial operating losses and potential liquidity concerns despite positive stock price momentum"]
What changed in the latest 10-Q
AI-assisted comparison of IMDX's 10-Q filed 2026-05-13 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to February 20, 2026 Specimen Collection Agreement with national reference lab provider
- Statement that GraftAssureDx data package was submitted to FDA on March 25, 2026
- Statement that company is 'pursuing regulatory authorization in kidneys first'
- Mention of 'research and development labs in Nashville, Tennessee and Göttingen, Germany'
- Statement that company 'currently do not intend to commercialize either [DetermaIO and DetermaCNI] in the next 12 months'
- Removed:
- Company full name 'Insight Molecular Diagnostics Inc., or iMDx' removed from opening Overview
- Mission statement changed from 'democratize access to novel molecular diagnostic testing to improve patient outcomes' to 'expand access to novel molecular diagnostic testing'
- Removal of phrase 'send-out-testing central laboratory model' changed to simply 'central laboratory model'
- Reference to Nashville, Tennessee laboratory changed to Franklin, Tennessee laboratory
- Extensive detail about GraftAssureCore performance ('can find donor kidney damage up to 11 months sooner')
- Detail about GraftAssureCore validation in 'three major solid organ transplant types (kidney, liver and heart)'
- Reference to MolDx positive coverage decision in August 2023 and commercial availability from January 2024
- Reference to December 2024 Medicare reimbursement confirmation for high-risk patients
- Detail about May 2025 reimbursement rate increase to $2,753 per result
- Reference to July 2024 commercialization beginning of GraftAssureIQ
- Statement about distribution through 'direct sales, partnering and distribution agreements, and licensing'
- Detailed description of DetermaIO application to checkpoint inhibitor drugs and tumor types
- Reference to 'kitted research product format of the underlying technology began proof-of-concept development in 2023'
- Statement expecting to 'begin commercializing our oncology product line, which includes DetermaIO'
- Description of 'world-renowned scientists' and 'world-renowned research scientists'
- References to operating premise about democratizing access and reducing cost of care
- Reference to expected IVD submission 'by the end of 2025'
- Reworded:
- Reference date changed from 'year ended December 31, 2024' to 'year ended December 31, 2025'
- Statement about consolidated financial statements changed from 'three and nine months ended September 30, 2025 and 2024' to 'three months ended March 31, 2026 and 2025'
- GraftAssureCore described as 'Our LDT, currently reimbursed by CMS and performed at our CLIA certified laboratory in Franklin, Tennessee' instead of detailed coverage decision and commercialization timeline
- GraftAssureDx described as 'The IVD kit currently in development' rather than under active clinical trial with submission expected
- Oncology section shortened from discussing specific development plans to stating 'currently we do not intend to commercialize either in the next 12 months'
- Laboratory location changed from 'Nashville, Tennessee' to 'Franklin, Tennessee' for primary services lab
- Removed language about 'world-renowned' scientists, replacing with general 'scientists' and 'research scientists whom we believe are leaders in their fields'
- Oncology description simplified from detailed therapeutic application examples to general statement about 'minimum amount of resources'
- Notes:
- The newer filing text appears truncated at the end of the Overview section, making complete assessment of later MD&A sections impossible
- Comparison is between Q2 2026 10-Q and Q3 2025 10-Q filings, representing different fiscal periods which may explain some narrative shifts
Risk Factors
- Added:
- Added reference to quarterly period ended March 31, 2026 in cautionary note (filed 2026-05-13)
- Added statement about company name change 'f/k/a Oncocyte Corporation' in cautionary note (filed 2026-05-13)
- Added reference to form 10-Q for quarter ended March 31, 2026 (filed 2026-05-13)
- Added reference to most recent Annual Report on Form 10-K for year ended December 31, 2025 in cautionary note (filed 2026-05-13)
- Added geographic scope clarification 'including within the U.S. and outside of the U.S.' to reimbursement bullet point (filed 2026-05-13)
- Removed:
- Removed 'Quarterly Report on Form 10-Q' specific reference to filing date in opening cautionary statement (older filing 2025-11-10 had unspecified quarter reference)
- Removed reference to form 10-K for year ended December 31, 2024; replaced with December 31, 2025 (filed 2026-05-13)
- Removed paragraph describing rebranding of VitaGraft assays to GraftAssure products (present in older filing 2025-11-10, removed in 2026-05-13)
- Removed financial data and balance sheet details from September 30, 2025 and December 31, 2024 (older filing dates replaced with March 31, 2026 and December 31, 2025 data)
- Reworded:
- Changed 'Risk Factors' reference from unspecified to 'Risk Factors' in Part I, Item 1A (filed 2026-05-13)
- Changed second bullet point from 'Centers for Medicare and Medicaid Services and other third-party payers' to include 'including within the U.S. and outside of the U.S.' (filed 2026-05-13)
- Changed page numbers for Item 1A Risk Factors from page 59 to page 53 (filed 2026-05-13)
- Notes:
- The two filings represent different quarterly periods (March 31, 2026 vs. September 30, 2025), making some financial data changes reflect period differences rather than substantive reporting changes
- Balance sheet and statements of operations reflect different reporting dates and therefore different financial positions and periods covered
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days12 buys ($3M) · 0 sells — 1 buying insider
Most recent open-market transaction: 2026-04-27. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMDX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
2 institutional 13F filers reported holding IMDX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 2
- Reported shares held 186,099
- Reported value $610,405
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 0 decreased, 2 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IMDX had 1,073,767 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IMDX had 3.28% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.14 days to cover at the same settlement.
- Reported short interest (shares) 1,073,767
- Short interest (% of shares outstanding) 3.28%
- Prior settlement (shares) 1,246,002
- Reported change -13.82%
- Days to cover (reported) 11.14
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Natera (NTRA)
- CareDx (CDNA)
- Eurofins Scientific (ERFSF)
- LabCorp (LH)
- Quest Diagnostics (DGX)
- Thermo Fisher Scientific (TMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMDX vs…
Frequently asked questions
What does Insight Molecular Diagnostics Inc. (IMDX) do?
Insight Molecular Diagnostics Inc. (formerly Oncocyte Corporation) is a diagnostics technology company developing molecular diagnostic test kits for organ transplant rejection monitoring and oncology applications. The company's primary focus is decentralized transplant testing through its GraftAssure family of assays, which measure donor-derived cell-free DNA (dd-cfDNA) using digital PCR instruments manufactured by Bio-Rad.
What sector is Insight Molecular Diagnostics Inc. (IMDX) in?
Insight Molecular Diagnostics Inc. (IMDX) is classified in the Health Care sector. Its industry is Molecular diagnostics / transplant rejection monitoring. It trades on NASDAQ.
Who are Insight Molecular Diagnostics Inc.'s (IMDX) competitors?
Notable peers of Insight Molecular Diagnostics Inc. (IMDX) include Natera, CareDx, Eurofins Scientific, LabCorp and Quest Diagnostics. This peer set is informational only — not financial advice.
Is Insight Molecular Diagnostics Inc. (IMDX) overbought or oversold right now?
Insight Molecular Diagnostics Inc. (IMDX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMDX come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.